Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. (Q52629914)

4 May 2018

title

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. (English)

1 reference

4 May 2018

1 reference

1

1 reference

4 May 2018

Giuseppe Ippolito

11

Giuseppe Ippolito

1 reference

Giovanni Battista Migliori

4 May 2018

12

Giovanni Battista Migliori

1 reference

4 May 2018

9

Peter Mwaba

1 reference

4 May 2018

Nathan Kapata

8

Nathan Kapata

1 reference

4 May 2018

Francine Ntoumi

6

Francine Ntoumi

1 reference

4 May 2018

14

Alimuddin Zumla

1 reference

4 May 2018

Sayoki Mfinanga

7

Sayoki Mfinanga

1 reference

4 May 2018

Gerhard Walzl

3

Gerhard Walzl

1 reference

4 May 2018

author name string

Nelita du Plessis

2

1 reference

4 May 2018

Michael J Vjecha

4

1 reference

4 May 2018

Martin Rao

5

1 reference

4 May 2018

Timothy D McHugh

10

1 reference

4 May 2018

Markus J Maeurer

13

1 reference

4 May 2018

publication date

23 March 2018

1 reference

4 May 2018

Lancet Infectious Diseases

published in

1 reference

4 May 2018

Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Treatment Outcomes in Multidrug-Resistant Tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Clinical trial research in focus: overcoming barriers in MDR-TB clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Target regimen profiles for treatment of tuberculosis: a WHO document.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Recent developments in the diagnosis and management of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Methionine and vitamin B-complex ameliorate antitubercular drugs-induced toxicity in exposed patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Classifying new anti-tuberculosis drugs: rationale and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Classification of antituberculosis drugs: a new proposal based on the most recent evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Treatment outcomes of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

β-Lactams against Tuberculosis--New Trick for an Old Dog?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

The Need for Global Regulation of Antibiotics: The Case of a Generic Oral Penem.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Three months of rifapentine and isoniazid for latent tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Towards host-directed therapies for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Inhalable Particles for "Pincer Therapeutics" Targeting Nitazoxanide as Bactericidal and Host-Directed Agent to Macrophages in a Mouse Model of Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Metformin as adjunct antituberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Biogenesis and Function of T Cell-Derived Exosomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Tumour-vessel-on-a-chip models for drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Immune regulation by glucocorticoids.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Tuberculosis Meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Glucocorticoids Suppress Antimicrobial Autophagy and Nitric Oxide Production and Facilitate Mycobacterial Survival in Macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Prostaglandins and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

The antiinflammatory effects of statins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

The effects of statin use on the development of tuberculosis among patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Statin adjunctive therapy shortens the duration of TB treatment in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Phosphodiesterase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

FDA-approved small-molecule kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Metformin activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complex

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Immune checkpoints and their inhibition in cancer and infectious diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

CTLA-4 blockade enhances the immune response induced by mycobacterial infection but does not lead to increased protection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Vitamin D deficiency and the risk of tuberculosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Vitamin D as Adjunctive Host-Directed Therapy in Tuberculosis: A Systematic Review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Vitamins A & D inhibit the growth of mycobacteria in radiometric culture

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Randomized controlled trial of zinc and vitamin A as co-adjuvants for the treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Impact of Vitamin A and Carotenoids on the Risk of Tuberculosis Progression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

All-trans retinoic acid-triggered antimicrobial activity against Mycobacterium tuberculosis is dependent on NPC2.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Totally drug-resistant tuberculosis and adjunct therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

The introduction of mesenchymal stromal cells induces different immunological responses in the lungs of healthy and M. tuberculosis infected mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Increased frequency of myeloid-derived suppressor cells during active tuberculosis and after recent mycobacterium tuberculosis infection suppresses T-cell function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Granulocytic myeloid derived suppressor cells expansion during active pulmonary tuberculosis is associated with high nitric oxide plasma level

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Perturbed microRNA Expression by Mycobacterium tuberculosis Promotes Macrophage Polarization Leading to Pro-survival Foam Cell.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Targeting microRNAs as key modulators of tumor immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Adalimumab treatment of life-threatening tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2818%2930110-5

7 January 2021

10.1016/S1473-3099(18)30110-5

Identifiers

DOI

1 reference

4 May 2018

1 reference

4 May 2018